Product/Composition:- | Acalabrutinib |
---|---|
Strength:- | 100 mg |
Form:- | Oral Capsules |
Reference Brands:- | Calquence® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Acalabrutinib Capsules (brand name Calquence®) are used to treat CLL and MCL, targeting BTK to block malignant B-cell growth. Available in 100 mg strength, they are manufactured under GMP standards and approved in both US and EU markets as a reliable oncology therapy.
Acalabrutinib Capsules are a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By targeting and inhibiting BTK, Acalabrutinib prevents the survival and proliferation of malignant B-cells. Marketed under the brand name Calquence®, Acalabrutinib offers an effective solution for patients who have not responded to other treatments or as a first-line therapy. Available in a 100 mg oral capsule strength, Acalabrutinib is manufactured under GMP-compliant conditions, providing a reliable oncology treatment for US and EU markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications